Início/Ações/NLSP

NLSP

USD

NLS Pharmaceutics Ltd. Ordinary Shares

$0.762-0.008 (-1.039%)

Preço em tempo real

Healthcare

Biotecnologia

Suíça

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado

Fundamentos da empresa

Estatísticas de negociação

Métricas de mercado

Abertura

$0.770

Máximo

$0.830

Mínimo

$0.760

Volume

0.00M

Fundamentos da empresa

Capitalização de mercado

4.0M

Setor

Biotecnologia

País

Switzerland

Estatísticas de negociação

Volume médio

0.07M

Bolsa de valores

NCM

Moeda

USD

Faixa de 52 semanas

Mínimo $0.76Atual $0.762Máximo $43.4

Notícias relacionadas

30/10/2025 · 20:15

PR Newswire

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger

NewcelX Ltd. ("NewcelX" or the "Company") completed the previously announced merger transaction, pursuant to that certain Agreement of Merger and...

Ver mais

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger

30/10/2025 · 11:00

PR Newswire

NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs

NLS Pharmaceutics Ltd. (Nasdaq: NLSP)(Nasdaq: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and...

Ver mais

NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs

29/10/2025 · 10:00

PR Newswire

NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...

Ver mais

NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem

29/10/2025 · 07:53

PR Newswire

NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company") and Kadimastem Ltd. (TASE: KDST) ("Kadimastem") today announced that,...

Ver mais

NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares

27/10/2025 · 11:00

PR Newswire

NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies

NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and...

Ver mais

NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies

PR Newswire

23/10/2025 · 10:01

NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025

NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central...